Pancreas cancer: Therapeutic trials in metastatic disease.
James W SmithyEileen M O'ReillyPublished in: Journal of surgical oncology (2021)
Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2-mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism, tumor microenvironment, and the immune system, and selected approaches are reviewed herein.
Keyphrases
- squamous cell carcinoma
- small cell lung cancer
- cancer therapy
- papillary thyroid
- cardiovascular events
- type diabetes
- squamous cell
- dna repair
- advanced non small cell lung cancer
- young adults
- oxidative stress
- phase ii
- wild type
- childhood cancer
- coronary artery disease
- epidermal growth factor receptor
- study protocol
- phase iii